Wealth Enhancement Advisory Services LLC has purchased 165,451 shares of
Royalty Pharma PLC (RPRX), and despite some entities related to the RPRX CFO selling 34,791 shares under a 10b5-1 plan, numerous firms are increasing their stake. This includes
Nordea Investment Management AB,
JPMorgan Chase & Co, and
Capital International Investors. Moreover, firms such as
WBI Investments LLC and
Braidwell LP have initiated significant new positions in RPRX. Despite these insider sales,
Morgan Stanley maintains a buy rating on the company, with a projected target price of $55. RPRX is also making major
leadership changes, introducing new AI and Asian market specialists. Following strong financial performance, RPRX has increased its dividend and the company's 2026 growth outlook has exceeded expectations. Expectations for RPRX's Q4 earnings are positive. Furthermore, there is consistent interest by leading banks, such as Bank of America and UBS, in RPRX due to its solid one-year share price performance and better-than-expected 2025 revenue guidance. RPRX is also entering strategic partnerships, including a $2B deal with Revolution Medicines.
Royalty Pharma Stocks News Analytics from Fri, 29 Aug 2025 07:00:00 GMT to Sat, 28 Mar 2026 12:14:33 GMT -
Rating 7
- Innovation 5
- Information 8
- Rumor -7
